tag novel-targeted-cancer-treatments 
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.
European Pharmaceutical Review
AUGUST 24, 2022
ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. cancer agent or disease-relevant toxin. 1 While the first successes underscored the potential of this class of targeted therapies, they also revealed bottle?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 2, 2023
Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.
European Pharmaceutical Review
NOVEMBER 10, 2022
The biological characterisation of complex medicines is fundamental to translate these novel therapeutics and associated drug delivery technologies into the clinic; to understand the interplay with biological systems and to evaluate new formulations?. Modifying or developing targeting moieties is necessary to improve extrahepatic delivery.
European Pharmaceutical Review
DECEMBER 27, 2023
Product distribution requires shipping of apheresis starter materials, either cryopreserved or fresh (depending on the product), to the manufacturing site as well as shipping of final cryopreserved products to treatment centres. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change.
Expert insights. Personalized for you.
52 
Let's personalize your content